You are here

PLoS Med DOI:10.1371/journal.pmed.0030485

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.

Publication TypeJournal Article
Year of Publication2006
AuthorsLee, JC, Vivanco, I, Beroukhim, R, H Y Huang, J, Feng, WL, Debiasi, RM, Yoshimoto, K, King, JC, Nghiemphu, P, Yuza, Y, Xu, Q, Greulich, H, Thomas, RK, J Paez, G, Peck, TC, Linhart, DJ, Glatt, KA, Getz, G, Onofrio, R, Ziaugra, L, Levine, RL, Gabriel, S, Kawaguchi, T, O'Neill, K, Khan, H, Liau, LM, Nelson, SF, P Rao, N, Mischel, P, Pieper, RO, Cloughesy, T, Leahy, DJ, Sellers, WR, Sawyers, CL, Meyerson, M, Mellinghoff, IK
JournalPLoS Med
Volume3
Issue12
Pagese485
Date Published2006 Dec
ISSN1549-1676
KeywordsAnimals, Astrocytes, Binding Sites, Cell Line, Tumor, Cell Survival, Cells, Cultured, Erlotinib Hydrochloride, Gene Expression Regulation, Neoplastic, Glioblastoma, Humans, Mice, Mice, Nude, Models, Molecular, Mutation, Missense, Neoplasms, Experimental, NIH 3T3 Cells, Phosphorylation, Protein Binding, Protein Kinase Inhibitors, Protein Structure, Tertiary, Quinazolines, Receptor, Epidermal Growth Factor, Reverse Transcriptase Polymerase Chain Reaction, Transfection
Abstract

BACKGROUND: Protein tyrosine kinases are important regulators of cellular homeostasis with tightly controlled catalytic activity. Mutations in kinase-encoding genes can relieve the autoinhibitory constraints on kinase activity, can promote malignant transformation, and appear to be a major determinant of response to kinase inhibitor therapy. Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase inhibitor therapy.

METHODS AND FINDINGS: Encouraged by the promising clinical activity of epidermal growth factor receptor (EGFR) kinase inhibitors in treating glioblastoma in humans, we have sequenced the complete EGFR coding sequence in glioma tumor samples and cell lines. We identified novel missense mutations in the extracellular domain of EGFR in 13.6% (18/132) of glioblastomas and 12.5% (1/8) of glioblastoma cell lines. These EGFR mutations were associated with increased EGFR gene dosage and conferred anchorage-independent growth and tumorigenicity to NIH-3T3 cells. Cells transformed by expression of these EGFR mutants were sensitive to small-molecule EGFR kinase inhibitors.

CONCLUSIONS: Our results suggest extracellular missense mutations as a novel mechanism for oncogenic EGFR activation and may help identify patients who can benefit from EGFR kinase inhibitors for treatment of glioblastoma.

URLhttp://dx.plos.org/10.1371/journal.pmed.0030485
DOI10.1371/journal.pmed.0030485
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/17177598?dopt=Abstract

Alternate JournalPLoS Med.
PubMed ID17177598
PubMed Central IDPMC1702556
Grant ListR01 CA116020 / CA / NCI NIH HHS / United States
T32 CA009172 / CA / NCI NIH HHS / United States